Bayer's Pharmaceutical Division Shows Promising Momentum

Bayer reaffirms growth targets as Kerendia expands into heart failure. Supreme Court ruling on Roundup litigation in June could ease major financial pressure.

Bayer's recent pharmaceutical media event in Berlin presented a series of strategic updates, from regulatory approvals to confirmed growth targets. While the operational core of the business demonstrates clear strength, the company's share price continues to face separate, significant headwinds.

Legal Overhang and Financial Pressure

The positive developments within the pharmaceuticals unit are set against a challenging corporate backdrop. Litigation concerning the herbicide Roundup remains a substantial burden, with over 100,000 claims having cost the company more than $11 billion to date. For the 2026 fiscal year, Bayer anticipates a deeply negative free cash flow, with litigation-related payouts alone expected to reach approximately five billion euros.

A critical juncture arrives on April 27, when oral arguments begin before the U.S. Supreme Court. A ruling is anticipated in the second half of June. A decision in Bayer’s favor would remove the legal foundation for thousands of future claims, which would have a materially positive impact on the company's financial statements.

Key Drug Approval Expands Market Reach

Just ahead of the media day, the European Commission approved a second indication for Kerendia (finerenone). The drug is now authorized for treating heart failure with a left ventricular ejection fraction of at least 40%. Its previous EU approval was limited to chronic kidney disease in patients with Type 2 diabetes.

This expansion is supported by the Phase III FINEARTS-HF study, which involved around 6,000 patients. The trial demonstrated that finerenone significantly reduced cardiovascular death and heart failure events compared to a placebo. The newly addressable patient population in Europe is estimated at 7.5 million people, a group that has had few guideline-recommended treatment options until now.

Already a major growth driver, Kerendia saw its revenue surge by nearly 93% to €264 million in the fourth quarter of 2025. Bayer's long-term peak sales forecast for the drug stands at three billion euros annually.

Confirmed Financial Targets and Pipeline Catalysts

Pharmaceuticals chief Stefan Oelrich reaffirmed the division's mid-term objectives during the event. The company aims to return to mid-single-digit sales growth from 2027 onward. The operating margin is projected to begin improving from 2028, targeting a rise toward 30% by 2030.

This trajectory is expected to be powered by a cluster of newer products, including the prostate cancer treatment Nubeqa, Kerendia, the heart drug Beyonttra, and Lynkuet. Further potential lies with the anticoagulant asundexian, which has received Fast-Track designation from the FDA following a successful stroke study program. Initial data from the Phase 2 gene therapy study AB-1002, conducted by subsidiary AskBio, are expected in the first half of 2027.

Leadership and Operational Strategy

Bayer is also bolstering its leadership for the crucial U.S. market. Effective May 1, 2026, Nelson Ambrogio will assume leadership of Bayer U.S. Pharmaceuticals, moving from his role as head of the global Radiology business unit. In light of current tariff policies, the company is evaluating an expansion of its U.S. manufacturing capacity.

Analyst perspectives reflect a cautious optimism focused on operational performance. Barclays maintains an "Overweight" rating with a price target of €48, anticipating a strong operational result in the quarterly report due on May 12, 2026. UBS expresses even greater confidence, citing a fair value of €52 per share. Whether the operational recovery within the pharma division can restore broader confidence in Bayer's equity will be heavily influenced by the U.S. Supreme Court proceedings beginning April 27.